Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1

Acta Oncologica

Volumn 50, Issue 3, 2011, Pages 329-337

  Edlund, Per ^a   Ahlgren, Johan ^a   Bjerre, Karsten ^b   Andersson, Michael ^c   Bergh, Jonas ^d   Mouridsen, Henning ^c   Holmberg, Stig B ^e   Bengtsson, Nils Olof ^f   Jakobsen, Erik ^g   Møller, Susanne ^b   Lindman, Henrik ^h   Blomqvist, Carl ^h,i  

^a GÄVLE HOSPITAL   (Sweden)

^b DBCG Registry   (Denmark)

^c Rigshospitalet   (Denmark)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^g LILLEBAELT HOSPITAL   (Denmark)

^h UPPSALA UNIVERSITY HOSPITAL   (Sweden)

ⁱ HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; MESNA;

ADULT; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; DENMARK; DIARRHEA; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEASIBILITY STUDY; FEMALE; FEVER; HEART ARREST; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SWEDEN; THROMBOCYTOPENIA; VOMITING;

EID: 79952680409     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2011.554435     Document Type: Article

References (25)

1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687-717.
2. Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998;90:1205-11. (Pubitemid 28407086)
3. Fumoleau P, Roche H, Kerbrat P, et al. Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann Oncol 2006;17:85-92. (Pubitemid 43033845)
4. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-83. (Pubitemid 46594124)
5. Focan C, Andrien JM, Closon MT, et al. Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: A prospective randomized trial. J Clin Oncol 1993;11:1253-63. (Pubitemid 23199127)
6. Brufman G, Colajori E, Ghilezan N, et al. Doubling epirubicin dose intensity (100 mg/m 2 versus 50 mg/m 2 ) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group. Ann Oncol 1997;8:155-62. (Pubitemid 27112883)
7. Bonneterre J, Roche H, Kerbrat P, et al. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2005;23:2686-93. (Pubitemid 46179458)
8. Baker SD, Verweij J, Rowinsky EK, et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst 2002;94:1883-8. (Pubitemid 36104633)
9. Gurney H. Developing a new framework for dose calculation. J Clin Oncol 2006;24:1489-90. (Pubitemid 46638768)
10. Gurney HP, Ackland S, Gebski V, Farrell G. Factors affecting epirubicin pharmacokinetics and toxicity: Evidence against using body-surface area for dose calculation. J Clin Oncol 1998;16:2299-304. (Pubitemid 28309020)
11. Jakobsen P, Bastholt L, Dalmark M, et al. A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement. Cancer Chemother Pharmacol 1991;28:465-9.
12. Sandstrom M, Freijs A, Larsson R, et al. Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. J Clin Oncol 1996;14:1581-8. (Pubitemid 26134217)
13. Sandstrom M, Lindman H, Nygren P, Johansson M, Bergh J, Karlsson MO. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin- cyclophosphamide regimen in breast cancer patients. Cancer Chemother Pharmacol 2006;58:143-56.
14. Meinardi MT, Van Der Graaf WT, Gietema JA, et al. Evaluation of long term cardiotoxicity after epirubicin containing adjuvant chemotherapy and locoregional radiotherapy for breast cancer using various detection techniques. Heart 2002;88:81-2. (Pubitemid 34665011)
15. Praga C, Bergh J, Bliss J, et al. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: Correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 2005; 23:4179-91. (Pubitemid 46211324)
16. Cameron DA, Massie C, Kerr G, Leonard RC. Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 2003;89:1837-42. (Pubitemid 37533256)
17. Colleoni M, Price K, Castiglione-Gertsch M, et al. Doseresponse effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group. Eur J Cancer 1998;34:1693-700.
18. Mayers C, Panzarella T, Tannock IF. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 2001;91:2246-57. (Pubitemid 32552809)
19. Poikonen P, Saarto T, Lundin J, Joensuu H, Blomqvist C. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 1999;80:1763-6. (Pubitemid 29389629)
20. Saarto T, Blomqvist C, Rissanen P, Auvinen A, Elomaa I. Haematological toxicity: A marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 1997;75:301-5. (Pubitemid 27019578)
21. Bergh J, Wiklund T, Erikstein B, et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrowsupported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomised trial. Scandinavian Breast Group 9401 study. Lancet 2000;356:1384-91.
22. Wilking N, Lidbrink E, Wiklund T, et al. Long-term followup of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy. Ann Oncol 2007;18:694-700. (Pubitemid 46523273)
23. de Azambuja E, Paesmans M, Beauduin M, et al. Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicenter study. J Clin Oncol 2009;27:720-5.
24. Margolin S, Bengtsson NO, Carlsson L, et al. A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/ tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer. Acta Oncol 2011;50:35-41.
25. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001; 19:602-11.